GlassScriptPhysician profile
Erin Petersen
NPI 1508392366
$2,322.18
in general payments reported to CMS, 2019-2025
23 companies · $844 in 2025
The $844 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2021: $132 · 2022: $302 · 2023: $353 · 2024: $556 · 2025: $844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,753.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,752.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $509.09 | 2019-2025 | Tryptyr, Lensx, Clareon |
| Sun Pharmaceutical Industries INC. | $405.38 | 2021-2025 | Cequa |
| Johnson & Johnson Surgical Vision, INC. | $153.37 | 2024-2025 | Tecnis Simplicity |
| Oyster Point Pharma, INC. | $135.30 | 2022-2023 | Tyrvaya |
| Abbvie INC. | $130.52 | 2022-2023 | |
| Amgen INC. | $120.56 | 2025 | Uplizna |
| Allergan, INC. | $109.19 | 2022 | |
| Mallinckrodt Hospital Products INC. | $103.98 | 2023-2025 | Acthar |
| Biotissue Holdings INC. | $102.02 | 2023-2024 | |
| Ani Pharmaceuticals, INC. | $69.15 | 2024-2025 | Purified Cortrophin Gel |
| Rayner Intraocular Lenses Limited | $65.57 | 2024-2025 | Omidria, Rayone Aspheric, Rayone Emv |
| Astellas Pharma US INC | $59.37 | 2024 | Izervay |
| Rxsight INC | $53.16 | 2023-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Ocular Therapeutix, INC. | $48.14 | 2023 | Dextenza |
| Harrow Eye, LLC | $38.37 | 2025 | Vevye |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $35.73 | 2024-2025 | Ultomiris, Soliris |
| Bausch & Lomb Americas INC. | $34.52 | 2024-2025 | Miebo, Xiidra |
| Glaukos Corporation | $33.43 | 2024-2025 | Istent Trabecular Micro-Bypass System Model Is3, Istent Inject W, Idosetr |
| Tarsus Pharmaceuticals, INC. | $31.85 | 2025 | Xdemvy |
| Sight Sciences, INC. | $24.92 | 2024 | Omni Surgical System |
| Eyevance Pharmaceuticals LLC | $22.61 | 2022 | |
| Genzyme Corporation | $20.67 | 2023 | |
| Johnson & Johnson Vision Care, INC. | $15.28 | 2023 | Acuvue |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Petersen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.